With the rapid pace of immunologic research, it is more important than ever for readers to understand rational immunodiagnosis, immunopro-phylaxis, and immunotherapy. This column is intended to help you ensure proper immunologic drug use in your practice.
Get full access to this article
View all access options for this article.
References
1.
GrabensteinJ.D.Immunizations for international travel, Part I. Hosp Pharm.1991; 26: 636–7,640-1,657.
2.
GrabensteinJ.D.Meningococcal vaccine: Outbreaks, travel, and more. Hosp Pharm.1997; 32: 1219–23,1306.
3.
RosensteinN.E., PerkinsB.A., StephenD.S.Meningococcal disease. N Engl J Med.2001; 344: 1378–88.
4.
PollardA.J., FraschC.Development of natural immunity to Neisseria meningitidis. Vaccine.2001; 19: 1327–46.
5.
Advisory Committee on Immunization Practices.Prevention and control of meningococcal disease and meningococ-cal disease and college students. Mor Mortal Wkly Rep CDC Surveill Summ.2000; 49(RR-5): 1–20.
ChinJ., ed. Control of Communicable Diseases Manual.17th ed.Washington, DC: American Public Health Association; 2000.
8.
Meningococcal Disease Surveillance GroupAnalysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis.1976; 134: 201–4.
9.
Riewerts EriksenN.H., EspersenF., LaursenL.Nosocomial outbreak of group C meningococcal disease. BMJ.1989; 298: 568–9.
10.
GrabensteinJ.D.Overcoming immunization disparities based on race and ethnicity. Hosp Pharm.1999; 34: 550, 553-6,559.
HoyneA.L.Intravenous treatment of meningococcic meningitis with meningo-coccus antitoxin. JAMA.1936; 107: 478–81.
16.
FlexnerS.The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med.1913; 17: 553–76.
17.
GotschlichE.C., GoldschneiderI., ArtensteinM.S.Human immunity to the meningococcus: IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med.1969; 129: 1367–83.
18.
ArtensteinM.S., GoldR., ZimmerlyJ.G.Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med.1970; 282: 417–20.
19.
GrabensteinJ.D.ImmunoFacts: Vaccines and Immunologic Drugs.23rd rev.St. Louis: Facts and Comparisons; August 2001.
20.
Centers for Disease Control and PreventionHealth Information for International Travel 2001-02.Washington, DC: GPO; 2001.
21.
FraschC.E.Vaccines for prevention of meningococcal disease. Clin Microbiol Rev.1989; 2: S134–8.
22.
Advisory Committee on Immunization Practices.Recommendations of the Advisory Committee on Immunization Practices: Use of vaccines and immune globulins in persons with altered immunocom-petence. Mor Mortal Wkly Rep CDC Sur-veill Summ.1993; 42(RR-4): 1–18.
23.
American College of Physicians.Guide for Adult Immunization.3rd ed.Philadelphia: American College of Physicians; 1994, 49–55.
24.
HarrisonL.H.Preventing meningococ-cal infection in college students. Clin Infect Dis.2000; 30: 648–51.
25.
HarrisonL.H., DwyerD.M., MaplesC.T.Risk of meningococcal infection in college students. JAMA.1999; 281: 1906–10.
26.
American Academy of Pediatrics.Meningococcal disease prevention and control strategies for practice-based physicians. Addendum: Recommendations for college students. Pediatrics.2000; 106: 1500–4.
27.
JacksonL.A., SchuchatA., GorskyR.D.Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Publiv Health.1995; 85: 843–5.
28.
UK Communicable Disease Surveillance Centre.Vaccination programme for group C meningococcal infection is launched. Comm Dis Rep Wkly.1999; 9: 261–2,264.
29.
UK Communicable Disease Surveillance Centre.First phase of group C meningococcal vaccination programme to start in November. Comm Dis Rep Wkly.1999; 9: 387, 390.
30.
UK Communicable Disease Surveillance Centre.Meningococcal disease falls in vaccine recipients. Comm Dis Rep Wkly. 2000; 10: 133, 136.
31.
UK Communicable Disease Surveillance Centre.Safety of group C meningo-coccal vaccine. Comm Dis Rep Wkly.2000; 10: 311, 314.
32.
Anonymous.Aventis Pasteur MSD adds Chiron's meng C and flu vaccines to portfolio. FDC Reports.2000; 62(Jul 24): 23.
33.
RamsayM.E., AndrewsN., KaczmarskiE.B.Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet.2001; 357: 195–6.
BorrowR., AndrewsN., GoldblattD.Serological basis for use of meningo-coccal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection. Infect Immunity.2001; 69: 1568–73.
36.
LiebermanJ.M., ChiuS.S., WongV.K.Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: A randomized controlled trial. JAMA.1996; 275: 1499–503.
37.
RichmondP., GoldblattD., FuscoP.C.Safety and immunogenicity of a new Neisseria meningitidis serogroup Ctetanus toxoid conjugate vaccine in healthy adults. Vaccine.1999; 18: 641–6.
38.
RomeroJ.D., OutschoornI.M.Current status of meningococcal group B vaccine candidates: Capsular or noncapsular?Clin Microbiol Rev.1994; 7: 559–75.
39.
BjuneG., HoibyE.A., GronnesbyJ.K.Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet.1991; 338: 1093–6.
40.
SierraG.V.G., CampaH.C., VarcacelN.M.Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann (Oslo).1991; 14: 195–210.
41.
BoslegoJ.B., GarciaJ., CruzC.Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15: P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine.1995; 13: 821–9.
42.
TapperoJ.W., LagosR., BallesterosImmunogenicity of two serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. JAMA.1999; 281: 1520–7.
43.
GrabensteinJ.D.Immunization from the perspective of a millennium. Hosp Pharm.2000; 35: 619–30.
44.
LinF.Y., HoV.A., KhiemH.B.The efficacy of a Salmonella typhi Vi conjugate vaccine in two- to five-year-old children. N Engl J Med.2001; 344: 1263–9.
